TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06647953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT06524960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 1 mL of normal saline drawn up in a commercially available syringe.
Study: NCT05550584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).
Description: In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA
Description: Mechanical ventilation performed by a laringeal mask
Study: NCT06649981

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FMT capsule
Description: A lyophilized gut microbiota capsule derived from a rigorously screened, healthy, and physically active donor, free of gastrointestinal diseases, antibiotic use, and chronic conditions. The donor diverse microbiome is supported by a nutrient-rich diet and active lifestyle. The lyophilization process preserves microbial integrity, offering a high-potency dose aimed at restoring and optimizing the gut microbiome of older adults.~This intervention is specifically designed for older adults to enhance resilience to stress, cognitive function, muscular strength, and metabolic health. It is part of a controlled clinical study with follow-up assessments at weeks 1, 4, 8, and 20 post-intervention. This targeted approach distinguishes it from other microbiome-based therapies by focusing on comprehensive health benefits for an aging population.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule(s)
Description: A placebo capsule will be used in this study to serve as a control, allowing us to objectively assess the true effects of the lyophilized gut microbiota intervention. The use of a placebo is essential to eliminate bias and ensure that any observed outcomes can be confidently attributed to the actual intervention rather than to psychological or other non-specific effects.~The placebo capsule will be identical in appearance, size, shape, and color to the interventional capsule to maintain blinding for both participants and researchers. This ensures that neither group knows which capsule is being administered, thereby preserving the study's integrity and validity by preventing any expectations or beliefs from influencing the results.
Study: NCT04688983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ponatinib
Description: 30 mg QD starting day 1, given continuously unless interruption required for toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: 30 mg QD starting day 1, given continuously unless interruption required for toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: starting day 1, given orally at 400mg BID continuously for 8 weeks
Study: NCT06293690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.

Intervention type: DRUG
Group type: OTHER
Intervention: Toripalimab
Description: Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) on the second day. Two cycles in total.
Study: NCT05952427

Intervention type: OTHER
Intervention: ACE Questionnaire
Description: The only intervention consists of completing the validated ACE questionnaire

Intervention type: OTHER
Intervention: ACE Questionnaire
Description: The only intervention consists of completing the validated ACE questionnaire
Study: NCT06450275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 MG Film Coated Tablet
Description: 1 tablet of Dolutegravir 50mg film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tivicay 50mg, film-coated tablets
Description: 1 tablet of Dolutegravir 50mg film-coated tablets
Study: NCT05128942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.
Study: NCT05155098

Intervention type: OTHER
Intervention: secukinumab
Description: Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
Study: NCT06648434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zunsemetinib
Description: Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zunsemetinib
Description: Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.
Study: NCT05672992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spatial-frequency domain imaging (SFDI)
Description: SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spatial-frequency domain imaging (SFDI)
Description: SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
Study: NCT04974216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administration: IV at 375mg/m2 C1 to C6: D1
Study: NCT05907668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1401 (batoclimab)
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
Study: NCT05688904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Topical 4% Imipramine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT05282381

Intervention type: BEHAVIORAL
Intervention: DRS : Decision Regret Scale
Description: The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire.~Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation.
Study: NCT06198569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF EXERCISES
Description: Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strength exercises
Description: Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights
Study: NCT05085548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels (DL) 1,2,3
Description: ProAgio is administered to study participants by intravenous injections once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels (DL) 4,5,6
Description: ProAgio is administered to study participants by intravenous injections once every 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels (DL) 4,5,6
Description: ProAgio is administered to study participants by intravenous injections once every 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels 4a,5a,6a
Description: ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels 4a,5a,6a
Description: ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels 4a,5a,6a
Description: ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.
Study: NCT04749719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remotely supervised transcranial direct current stimulation
Description: Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: remotely supervised transcranial direct current stimulation
Description: Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
Study: NCT05213936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling with hairstyle
Description: Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling with conditioner and water emulsion
Description: Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
Study: NCT05566756

Intervention type: OTHER
Intervention: Ofatumumab
Description: There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
Study: NCT05873413

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivate-the-Bystander
Description: A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivate-the-Bystander+Alcohol
Description: A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-only Control
Description: A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
Study: NCT05546996

Intervention type: DEVICE
Group type: OTHER
Intervention: FlowSense
Description: Patients will have one or more existing external ventricular drains (EVDs). Phase B patients will additionally have an accessible (shaved) region of skin \>3 cm x 3 cm overlaying the EVD tubing.~Clinical data to be collected include: 1) total drainage volume1 over the 20-minute measurement period; 2) handheld ultrasound measurement of skin thickness2 over the EVD; and 3) an ICP waveform from a standard-of-care transducer, 4) dimensions (inner diameter and outer diameter) of tunneled catheter. Single patients may be measured multiple times during their admission; each measurement will be considered independent for analysis.
Study: NCT04980053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Intervention group Control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Intervention group Control group
Study: NCT05796570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Nucleoside metabolic inhibitor, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Nucleoside metabolic inhibitor, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
Study: NCT06516757

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boric Acid Suppository
Description: Participants will complete a baseline questionnaire and a vaginal pH test before using the product, and additional questionnaires and a pH test after 3 and 7 days of product use.
Study: NCT06143839

Intervention type: DRUG
Intervention: Vyxeos liposomal
Description: Standard of care JZP351 administered intravenously over 90 minutes.
Study: NCT05316038

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
Study: NCT05794464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation and/or electrical cardioversion
Description: Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
Study: NCT04598477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Oral prednisone tablets
Study: NCT05892679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks.
Study: NCT05496582

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT04597320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.
Study: NCT05476926

Intervention type: DRUG
Intervention: Faricimab
Description: Faricimab will be administered as per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Faricimab
Description: Faricimab will be administered as per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Faricimab
Description: Faricimab will be administered as per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Faricimab
Description: Faricimab will be administered as per local clinical practice and local labeling.

Intervention type: COMBINATION_PRODUCT
Intervention: Port Delivery System with Ranibizumab
Description: The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
Study: NCT04737941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothermal Ablation
Description: Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothermal Ablation
Description: Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foam Sclerotherapy
Description: Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foam Sclerotherapy
Description: Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
Study: NCT05509608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RM Electrode
Description: The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RM Electrode
Description: The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERG Jet Electrode
Description: The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERG Jet Electrode
Description: The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
Study: NCT04557618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagal nerve stimulation